Meritxell Bellet

5.6k total citations · 2 hit papers
70 papers, 2.1k citations indexed

About

Meritxell Bellet is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Meritxell Bellet has authored 70 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Meritxell Bellet's work include Advanced Breast Cancer Therapies (32 papers), HER2/EGFR in Cancer Research (23 papers) and Cancer Treatment and Pharmacology (21 papers). Meritxell Bellet is often cited by papers focused on Advanced Breast Cancer Therapies (32 papers), HER2/EGFR in Cancer Research (23 papers) and Cancer Treatment and Pharmacology (21 papers). Meritxell Bellet collaborates with scholars based in Spain, United States and United Kingdom. Meritxell Bellet's co-authors include Javier Cortés, Cristina Saura, José Baselga, Nicholas C. Turner, José Baselga, Violeta Serra, Marta Palafox, Martín A. Rivas, Judit Grueso and Christopher J. Lord and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Meritxell Bellet

68 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

2016 511 citations María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research profile →
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations José Baselga, Meritxell Bellet et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meritxell Bellet Spain	19	1.4k	988	656	618	358	70	2.1k
Manuel Ruíz‐Borrego Spain	19	1.3k 0.9×	961 1.0×	447 0.7×	771 1.2×	246 0.7×	97	1.9k
Jutta Steinseifer Switzerland	10	990 0.7×	495 0.5×	526 0.8×	484 0.8×	161 0.4×	15	1.5k
Peter Kabos United States	31	1.5k 1.0×	828 0.8×	1.0k 1.5×	740 1.2×	393 1.1×	100	2.5k
Seth A. Wander United States	25	1.5k 1.1×	1.1k 1.1×	1.3k 2.0×	791 1.3×	219 0.6×	108	2.9k
Eva Ciruelos Spain	15	1.5k 1.0×	1.4k 1.4×	924 1.4×	936 1.5×	183 0.5×	76	2.5k
Timothy Pluard United States	20	1.3k 0.9×	751 0.8×	534 0.8×	772 1.2×	125 0.3×	80	1.9k
Antonio Marchetti Italy	23	878 0.6×	715 0.7×	929 1.4×	594 1.0×	112 0.3×	39	1.8k
Sarah Heeson United Kingdom	11	1.5k 1.1×	624 0.6×	801 1.2×	445 0.7×	372 1.0×	23	2.4k
Jin‐Hee Ahn South Korea	25	938 0.7×	821 0.8×	549 0.8×	484 0.8×	88 0.2×	115	1.9k
Arlene Berman United States	22	1.3k 0.9×	474 0.5×	614 0.9×	534 0.9×	83 0.2×	47	2.4k

Countries citing papers authored by Meritxell Bellet

Since Specialization

Citations

This map shows the geographic impact of Meritxell Bellet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meritxell Bellet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meritxell Bellet more than expected).

Fields of papers citing papers by Meritxell Bellet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meritxell Bellet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meritxell Bellet. The network helps show where Meritxell Bellet may publish in the future.

Co-authorship network of co-authors of Meritxell Bellet

This figure shows the co-authorship network connecting the top 25 collaborators of Meritxell Bellet. A scholar is included among the top collaborators of Meritxell Bellet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meritxell Bellet. Meritxell Bellet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pérez-García, José Manuel, Meritxell Bellet, Miguel Gil‐Gil, et al.. (2025). Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 10(7). 105309–105309.

Guerrero‐Zotano, Ángel, Manuel Ruíz‐Borrego, Begoña Bermejo, et al.. (2024). Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study. ESMO Open. 9(10). 103733–103733. 1 indexed citations

Martínez-Jáñez, Noelia, Meritxell Bellet, Fernando Henao, et al.. (2024). First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN. Breast Cancer Research and Treatment. 206(2). 317–328. 4 indexed citations

Pistilli, Barbara, Meritxell Bellet, Lucia Del Mastro, et al.. (2024). OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.. Journal of Clinical Oncology. 42(16_suppl). TPS1135–TPS1135. 2 indexed citations

Ingalla, Ellen, Xiaosai Yao, Jennifer M. Giltnane, et al.. (2022). Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Science Translational Medicine. 14(663). eabo5959–eabo5959. 9 indexed citations

Bardia, Aditya, Ingrid A. Mayer, Eric P. Winer, et al.. (2022). The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 197(2). 319–331. 14 indexed citations

Brasó‐Maristany, Fara, Meritxell Bellet, Mafalda Oliveira, et al.. (2021). 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer. Annals of Oncology. 32. S27–S27. 1 indexed citations

Moore, Heather M., Valentina Boni, Meritxell Bellet, et al.. (2021). Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).. Journal of Clinical Oncology. 39(15_suppl). 577–577. 17 indexed citations

Wang, Shixiong, Baoyan Bai, Igor Chernukhin, et al.. (2020). The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. Oncogene. 39(40). 6300–6312. 3 indexed citations

10.

Mateo, Lídia, Miquel Duran‐Frigola, Albert Gris‐Oliver, et al.. (2020). Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine. 12(1). 78–78. 15 indexed citations

11.

Adamo, Bárbara, Meritxell Bellet, Laia Paré, et al.. (2019). Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research. 21(1). 108–108. 18 indexed citations

12.

Escrivá-de-Romaní, Santiago, Míriam Arumí, Meritxell Bellet, & Cristina Saura. (2018). HER2-positive breast cancer: Current and new therapeutic strategies. The Breast. 39. 80–88. 96 indexed citations

13.

Herrera-Abreu, María Teresa, Marta Palafox, Uzma Asghar, et al.. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 76(8). 2301–2313. 511 indexed citations breakdown →

14.

Gil‐Gil, Miguel, Meritxell Bellet, Serafín Morales, et al.. (2015). Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Research and Treatment. 151(3). 597–606. 39 indexed citations

15.

Ribi, Karin, Weixiu Luo, J. Bernhard, et al.. (2015). Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. Cancer Research. 75(9_Supplement). S3–9. 3 indexed citations

16.

Moy, Beverly, Patrick Neven, Fabienne Lebrun, et al.. (2014). Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. The Oncologist. 19(4). 348–349. 25 indexed citations

17.

Moy, Beverly, Patrick Neven, Fabienne Lebrun, et al.. (2014). Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. The Oncologist. 19(4). 346–347. 10 indexed citations

18.

Oliveira, Mafalda, Javier Cortés, Meritxell Bellet, et al.. (2012). Management of the axilla in early breast cancer patients in the genomic era. Annals of Oncology. 24(5). 1163–1170. 10 indexed citations

19.

Cortés, Javier, Virginia Calvo, Natalia Ramírez-Merino, et al.. (2011). Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Annals of Oncology. 23(5). 1130–1137. 52 indexed citations

20.

Baselga, José, Antonio Llombart‐Cussac, Meritxell Bellet, et al.. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of Oncology. 14(9). 1383–1390. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact